Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
Purpose
The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.
Condition
- End Stage Renal Disease
Eligibility
- Eligible Ages
- Between 18 Years and 85 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- English speaking - able to sign informed consent - able to arrange transportation to and from study site - without acute stroke, concussion or traumatic brain injury - without acute medical issues at the time of participation - At least 12 weeks post Kidney transplant surgery
Exclusion Criteria
- are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI) - have hearing or visual impairment - are unable to read, write, speak or understand English - have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics - taking Envarsus at the time of recruitment
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Conversion Group | Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made. |
|
| Control Group | Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression. |
|
Recruiting Locations
University of Kansas Medical Center
Kansas City, Kansas 66160
Kansas City, Kansas 66160
More Details
- Status
- Unknown status
- Sponsor
- University of Kansas Medical Center